ArticleThe Journal of family practice2020
PURL: NPH insulin: It remains a good option.
Article in The Journal of family practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Higher Order Structure Differences Among Insulin Crystalline Drugs Revealed by 2D heteronuclear NMR.ChemMedChem · 2024Article
- Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes.Journal of clinical medicine research · 2022Review
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
Abstract
NPH insulin holds its own against basal insulin analogs-and it's cheaper.
Indexed as
Identifiers
32182291PMC7156125What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.